

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (Currently Amended) A method for transplanting cells to a patient in need thereof, comprising:

- a) obtaining cells from a donor,
- b) obtaining recipient cells from the patient;
- c) contacting the donor cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2, and recipient cells from the patient such that the donor cells, the recipient cells, the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact for a period of time from about 1 to about 48 hours, thereby obtaining a mixture, and wherein the immunoglobulin specific to B7-2 can compete with the murine antibody 3D1 for binding to B7-2;
- d) combining b) and c) to form a mixture, and
- de) introducing the mixture of step d) ~~after the contacting step of c)~~ to the patient.

2. (Original) The method of Claim 1, wherein the cells from the donor are derived from bone marrow or blood.

3. (Original) The method of Claim 2, wherein the recipient cell is a lymphocyte.

4. (Currently Amended) The method of Claim 31, wherein the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact with the donor cells for a period of time is between about 12 hours and 48 hours.

5. (Original) The method of Claim 4, wherein the period of time is about 36 hours.

6. (Original) The method of Claim 1, wherein the patient has a disease that is selected from the group consisting of: a proliferative disease, anemia and myeloid dysplasia syndrome.

7. (Original) The method of Claim 6, wherein the proliferative disease is selected from the group consisting of: leukemia, lymphoma and cancer.

8. (Original) The method of Claim 6, wherein the anemia is selected from the group consisting of: sickle-cell anemia, thalassemia and aplastic anemia.

9. (Currently Amended) A method for transplanting cells to a patient in need thereof, comprising:

- a) obtaining cells from a donor,
- b) obtaining a tissue, an organ, or recipient cells from the patient,
- c) contacting the donor cells with an immunoglobulin specific to B7-1, an immunoglobulin specific to B7-2, and ~~the tissue, the organ, or the recipient cells that express MHC Class I antigen, B7-1 and B7-2 molecules, such that the donor cells, the tissue organ or recipient cells, the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact for a period of time from about 1 to about 48 hours, thereby obtaining a mixture, and~~ wherein the

immunoglobulin specific to B7-2 can compete with the murine antibody 3D1 for binding to B7-2

d) combining b) and c) to form a mixture, and

~~de)~~ introducing the mixture of step d) ~~after the contacting step of c)~~ to the patient.

10. (Original) The method of Claim 9, wherein the cells derived from the donor are derived from bone marrow, stem cells or immature blood cells.

11. (Original) The method of claim 1, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are humanized.

12. (New) The method of Claim 1, wherein the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact with the donor cells for a period of time between about 1 hour and 48 hours.

13. (New) The method of Claim 9, wherein the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact with the donor cells for a period of time between about 1 hour and 48 hours.

14. (New) The method of claim 9, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are humanized.

15. (New) A method for transplanting cells to a patient in need thereof, comprising:

- a) obtaining cells from a donor,
- b) obtaining recipient cells from the patient;

c) contacting the donor cells with an immunoglobulin specific to B7-1 and an immunoglobulin specific to B7-2, wherein the immunoglobulin specific to B7-2 has a higher affinity for B7-2 than hCTLA4Ig and the immunoglobulin specific to B7-1 has a higher affinity for B7-1 than hCTLA4Ig;

d) combining b) and c) to form a mixture, and

e) introducing the mixture of step d) to the patient.

16. (New) The method of Claim 15, wherein the cells from the donor are derived from bone marrow or blood.

17. (New) The method of Claim 16, wherein the recipient cell is a lymphocyte.

18. (New) The method of Claim 15, wherein the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact with the donor cells for a period of time between about 12 hours and 48 hours.

19. (New) The method of Claim 18, wherein the period of time is about 36 hours.

20. (New) The method of Claim 15, wherein the patient has a disease that is selected from the group consisting of: a proliferative disease, anemia and myeloid dysplasia syndrome.

21. (New) The method of Claim 20, wherein the proliferative disease is selected from the group consisting of: leukemia, lymphoma and cancer.

22. (New) The method of Claim 20, wherein the anemia is selected from the group consisting of: sickle-cell anemia, thalassemia and aplastic anemia.

23. (New) The method of Claim 15, wherein the immunoglobulin specific to B7-1, and the immunoglobulin specific to B7-2 are in contact with the donor cells for a period of time between about 1 hour and 48 hours.